BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SCYNEXIS, Inc. and TB Alliance Sign HEOS Software Agreement


6/16/2011 9:05:16 AM

RESEARCH TRIANGLE PARK, NC--(Marketwire - June 16, 2011) -

Drug discovery company SCYNEXIS, Inc. announced today that it has signed an agreement that provides TB Alliance with access to SCYNEXIS' proprietary HEOS® drug discovery software platform for use in the organization's global tuberculosis research activities.

HEOS is a SaaS, secure, cloud-based drug research information software platform that supports geographically-dispersed project scientists who may be in different organizations. It facilitates researchers' efforts to consolidate, manage, share and analyze -- with state-of-the-art tools -- complex drug discovery information on a global basis.

"SCYNEXIS is pleased that TB Alliance has chosen HEOS to support its worldwide network of researchers," said SCYNEXIS President and Chief Executive Officer Yves Ribeill. "In addition to being used for a number of years with SCYNEXIS' big pharma and biotech customers, HEOS has become the standard collaborative research software platform in the Global Health area."

About SCYNEXIS

SCYNEXIS delivers integrated, efficient and innovative drug discovery and development solutions to our global health and pharmaceutical partners. Our record of success is exemplified by the delivery of eleven pre-clinical drug candidates over the last five years. SCYNEXIS' teams are tailored to be especially effective in moving customer projects from concept to clinic, utilizing powerful proprietary technologies such as the HEOS® SaaS Software Platform for comprehensive drug discovery information management and the MEDCHEM-FACTORY® High-Throughput Synthesis and Purification Platform. Our fully-integrated contract research solutions include medicinal chemistry, advanced biological screening, in vitro pharmacology and ADMET-PK, bioanalytical and analytical chemistry, process chemistry and cGMP manufacturing.

Founded in 2000, SCYNEXIS is located in Research Triangle Park, North Carolina. To learn more, visit www.scynexis.com.

About HEOS
HEOS® is a cloud-based software suite that provides a comprehensive array of web-based drug research information management software which supports geographically distributed scientists and facilitates collaboration.

The complex process of transforming a hit into a clinical candidate involves data generated by a broad range of sources. The success of the project relies on the capability of the partners to easily, securely and efficiently access, share and communicate the right information at the right time. HEOS is a web portal that provides a secure and user-friendly data handling system. It allows all the involved collaborators to view results and make informed decisions.

HEOS is powered by Accelrys tools including Accord data cartridge and Pipeline Pilot which are provided under special arrangement by Accelrys for use in neglected disease research.

Reference: Informatics for neglected diseases collaborations - F Bost, RT Jacobs, P Kowalczyk. Current Opinion in Drug Discovery & Development 2010 13:286-296.


For further information, please contact:
SCYNEXIS, Inc.
Terry Marquardt
Executive Director
Market Development & Communications
terry.marquardt@scynexis.com
Tel: +1-919-544-8603

SCYNEXIS Media Contacts:
Rick Rountree
Rick Rountree Communications, Inc.
rick@rickrountree.com
Tel. +1 919-878-1144

Sarah Cavanaugh
MacDougall Biomedical Communications
scavanaugh@macbiocom.com
Tel. +1 781-235-3060



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES